Logo
ABBV logo
AbbVie Inc.
ABBV
179.44 (0.98%) 1.76
317.10(B)
Health Care
Biotechnology
AbbVie Inc. discovers develops manufactures and sells pharmaceuticals worldwide. The company offers Humira an injection for autoimmune and intestinal Behçet's diseases and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis psoriatic disease and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis ankylosing spondylitis atopic dermatitis axial spondyloarthropathy ulcerative colitis and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer endometriosis and central precocious puberty and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech Inc.; Evolveimmune Therapeutics Inc.; Genentech Inc.; and Tentarix Biotherapeutics LP. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.
Holdings:
Shares:
Cost basis:

AbbVie Inc. (ABBV) price target and intrinsic value estimate

ABBV's fair price estimate is $170.6

This valuation is based on a fair P/E of 15.9 and EPS estimates of $10.72

The median analyst price target for ABBV is $205.0.

Analyst price targets range from $165.0 to $240.0

Is ABBV overvalued or undervalued?

ABBV is currently trading at $179.44

ABBV is overvalued by 5% using the pevaluation method.

ABBV is undervalued by 12% compared to median analyst price targets.

Do you agree with this valuation?

Valuation

PEvaluation

Low $127.9
Median $170.6
High $213.2
Fair P/E
Margin of safety

Analyst valuation

Low $165.0
Median $205.0
High $240.0
Strong Buy6
Buy13
Hold10
Sell0
Strong Sell0

Discounted cash-flow

TTM FCFFCF est.Growth FCFTerminal FCF
10%
5%
5y
10%
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide
None/narrowMediumWideVery wide

Overview

Market data

Market cap:$317.10(B)
Enterprise value:$377.11(B)
Total Equity:$6.07(B)
Shares outstanding:1.77(B)
Div. yield:3.46%
P/S:5.71
P/E:62.52
P/FCF:20.30
P/B:52.62
EPS:$2.9
FCF per share:$8.8
Dividend per share:$6.2

Income (TTM)

RevenueGrossNet
Revenue$55.53(B)
Gross profit$39.06(B)
EBITDA$25.63(B)
Net income$5.12(B)
Gross margin70.3%
Net margin9.2%

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$143.42(B)
Total liabilities$137.35(B)
Cash & Short-term inv.$7.29(B)
Long-term debt$58.75(B)
Debt issued$19.97(B)
Debt repaid$-10.65(B)

Cash flow (TTM)

CFOCFICFF
FCF$15.62(B)
CapEx$-888.00(M)
Dividends paid$-10.90(B)
Stock issued$235.00(M)
Stock repurchased$-1.35(B)
Stock-based comp.$872.00(M)

Future Growth

Revenue

CAGR: 6.3%
FY+1$56.04(B)
FY+2$59.23(B)
FY+3$63.56(B)
FY+4$67.36(B)
FY+5$71.59(B)

Net Income

CAGR: 10.6%
FY+1$19.44(B)
FY+2$21.63(B)
FY+3$24.22(B)
FY+4$26.57(B)
FY+5$29.05(B)

EPS

CAGR: 10.8%
FY+1$10.94
FY+2$12.18
FY+3$13.65
FY+4$15.07
FY+5$16.50

FCF per share

CAGR: 13.5%
FY+1$10.85
FY+2$12.56
FY+3$14.21
FY+4$16.60
FY+5$18.02

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Shares (Basic)Shares (Diluted)
Per share data
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
ROICROAROCEROE
Market Cap.
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Market Cap.